Somatostatin receptor (SSTR) (SSTR)

Somatostatin receptors (SSTR1–SSTR5) are a family of five G protein-coupled receptors (GPCRs) that mediate the inhibitory actions of the peptide hormone somatostatin across various organ systems [1, 2, 5, 8]. These receptors are widely expressed in the central nervous system, endocrine glands, and the gastrointestinal tract, where they regulate the secretion of hormones such as growth hormone, insulin, and glucagon [5, 9, 11]. In oncology, SSTRs—particularly SSTR2 and SSTR5—are frequently overexpressed in neuroendocrine tumors (NETs), making them vital targets for both diagnostic imaging and therapy [3, 4, 9]. Synthetic somatostatin analogs like octreotide and lanreotide are used to control hormonal symptoms and inhibit tumor progression by binding to these receptors [1, 5, 12, 13]. Furthermore, the high density of SSTRs on tumor cells allows for the use of radiolabeled analogs in peptide receptor radionuclide therapy (PRRT), providing a targeted approach to treating metastatic disease [6, 9]. Beyond oncology, SSTRs are investigated for roles in metabolic disorders, inflammation, and neurological conditions [3, 5, 11]. The clinical utility of SSTR-targeted agents extends to the management of pituitary adenomas and certain types of brain tumors like meningiomas, where receptor density correlates with therapeutic response [10, 14]. Ongoing research is exploring the potential of SSTR antagonists and multi-receptor ligands to overcome resistance and improve outcomes in patients with heterogeneous tumor profiles [3, 5, 12].

Other names

Somatostatin receptor type 1Somatostatin receptor type 2Somatostatin receptor type 3Somatostatin receptor type 4Somatostatin receptor type 5SSTR1SSTR2SSTR3SSTR4SSTR5SRIF receptorSS-RSomatotropin release-inhibiting factor receptorGrowth hormone-inhibiting hormone receptor

Primarily agonism of SSTR subtypes (especially SSTR2 and SSTR5) leading to G protein-mediated inhibition of adenylate cyclase, reduction of intracellular cAMP, activation of potassium channels, and inhibition of voltage-gated calcium channels, which suppresses hormone secretion and cell proliferation; however, SSTR2 antagonists are also being developed to prevent hypoglycemia [1, 2, 3, 5, 13].